Loading…
Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration
Abstract Purpose To describe the development of an innovative process to deliver bacillus Calmette-Guérin (BCG) to an offsite urology clinic for bladder instillation. Summary The use of BCG, a live virus vaccine for treatment of patients with localized cancer of the urinary bladder, has created many...
Saved in:
Published in: | American journal of health-system pharmacy 2021-01, Vol.78 (1), p.60-64 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c3219-4dd08a44299481e79c8f2c36d4a1d1d4e2c1ff548edf18bdd231caeb821923ec3 |
container_end_page | 64 |
container_issue | 1 |
container_start_page | 60 |
container_title | American journal of health-system pharmacy |
container_volume | 78 |
creator | Szewczyk, Michael T Soefje, Scott A |
description | Abstract
Purpose
To describe the development of an innovative process to deliver bacillus Calmette-Guérin (BCG) to an offsite urology clinic for bladder instillation.
Summary
The use of BCG, a live virus vaccine for treatment of patients with localized cancer of the urinary bladder, has created many logistical problems for hospitals and infusion center pharmacies. Due to its short stability, the drug cannot be made ahead of time and coordination with a patient’s arrival at an infusion site is challenging. This becomes exceptionally challenging when a urology clinic has limited compounding capacity and/or is distant from the site of BCG medication preparation. This article describes an innovative process involving use of closed-system transfer devices (CSTDs) to allow for the administration of BCG in a urology clinic offsite from a medical center’s infusion center facilities.
Conclusion
The use of the CSTD allowed the patients to continue to receive bladder instillations at an offsite urology clinic without significantly disrupting compounding workflow at the small infusion center pharmacy that was the nearest to the clinic. |
doi_str_mv | 10.1093/ajhp/zxaa339 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2454131383</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ajhp/zxaa339</oup_id><sourcerecordid>2454131383</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3219-4dd08a44299481e79c8f2c36d4a1d1d4e2c1ff548edf18bdd231caeb821923ec3</originalsourceid><addsrcrecordid>eNp9kM1u1DAUhS0Eoj-wY428o4uG-tqejr2spj8gVWID6-jGvtGkOHFqO9NO34jn4MVINQO7sjp38Z1zpY-xDyA-g7DqDO_W49nTI6JS9hU7hIVaVNIK8Xq-xdJWUhh5wI5yvhMCpBHnb9mBUsICwPKQ4SVtKMSxp6Hw2HIceDcMcYOl2xD3FOZIW563uVDP25h4g64LYcp8haGnUqi6mX7_St3Am4DeU-Lo-27ocknzSBzesTcthkzv93nMflxffV99qW6_3XxdXdxWTkmwlfZeGNRaWqsN0NI600qnzr1G8OA1SQdtu9CGfAum8V4qcEiNmctSkVPH7GS3O6Z4P1Eudd9lRyHgQHHKtdQLDQqUUTN6ukNdijknausxdT2mbQ2ifpZaP0ut91Jn_ON-eWp68v_gvxZnQOyAhxgKpfwzTA-U6jVhKOuXNj_tKnEa___9DzP5lWw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2454131383</pqid></control><display><type>article</type><title>Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration</title><source>Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)</source><creator>Szewczyk, Michael T ; Soefje, Scott A</creator><creatorcontrib>Szewczyk, Michael T ; Soefje, Scott A</creatorcontrib><description>Abstract
Purpose
To describe the development of an innovative process to deliver bacillus Calmette-Guérin (BCG) to an offsite urology clinic for bladder instillation.
Summary
The use of BCG, a live virus vaccine for treatment of patients with localized cancer of the urinary bladder, has created many logistical problems for hospitals and infusion center pharmacies. Due to its short stability, the drug cannot be made ahead of time and coordination with a patient’s arrival at an infusion site is challenging. This becomes exceptionally challenging when a urology clinic has limited compounding capacity and/or is distant from the site of BCG medication preparation. This article describes an innovative process involving use of closed-system transfer devices (CSTDs) to allow for the administration of BCG in a urology clinic offsite from a medical center’s infusion center facilities.
Conclusion
The use of the CSTD allowed the patients to continue to receive bladder instillations at an offsite urology clinic without significantly disrupting compounding workflow at the small infusion center pharmacy that was the nearest to the clinic.</description><identifier>ISSN: 1079-2082</identifier><identifier>EISSN: 1535-2900</identifier><identifier>DOI: 10.1093/ajhp/zxaa339</identifier><identifier>PMID: 33091117</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>American journal of health-system pharmacy, 2021-01, Vol.78 (1), p.60-64</ispartof><rights>American Society of Health-System Pharmacists 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2020</rights><rights>Copyright Oxford University Press 2020.</rights><rights>American Society of Health-System Pharmacists 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3219-4dd08a44299481e79c8f2c36d4a1d1d4e2c1ff548edf18bdd231caeb821923ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33091117$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Szewczyk, Michael T</creatorcontrib><creatorcontrib>Soefje, Scott A</creatorcontrib><title>Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration</title><title>American journal of health-system pharmacy</title><addtitle>Am J Health Syst Pharm</addtitle><description>Abstract
Purpose
To describe the development of an innovative process to deliver bacillus Calmette-Guérin (BCG) to an offsite urology clinic for bladder instillation.
Summary
The use of BCG, a live virus vaccine for treatment of patients with localized cancer of the urinary bladder, has created many logistical problems for hospitals and infusion center pharmacies. Due to its short stability, the drug cannot be made ahead of time and coordination with a patient’s arrival at an infusion site is challenging. This becomes exceptionally challenging when a urology clinic has limited compounding capacity and/or is distant from the site of BCG medication preparation. This article describes an innovative process involving use of closed-system transfer devices (CSTDs) to allow for the administration of BCG in a urology clinic offsite from a medical center’s infusion center facilities.
Conclusion
The use of the CSTD allowed the patients to continue to receive bladder instillations at an offsite urology clinic without significantly disrupting compounding workflow at the small infusion center pharmacy that was the nearest to the clinic.</description><issn>1079-2082</issn><issn>1535-2900</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kM1u1DAUhS0Eoj-wY428o4uG-tqejr2spj8gVWID6-jGvtGkOHFqO9NO34jn4MVINQO7sjp38Z1zpY-xDyA-g7DqDO_W49nTI6JS9hU7hIVaVNIK8Xq-xdJWUhh5wI5yvhMCpBHnb9mBUsICwPKQ4SVtKMSxp6Hw2HIceDcMcYOl2xD3FOZIW563uVDP25h4g64LYcp8haGnUqi6mX7_St3Am4DeU-Lo-27ocknzSBzesTcthkzv93nMflxffV99qW6_3XxdXdxWTkmwlfZeGNRaWqsN0NI600qnzr1G8OA1SQdtu9CGfAum8V4qcEiNmctSkVPH7GS3O6Z4P1Eudd9lRyHgQHHKtdQLDQqUUTN6ukNdijknausxdT2mbQ2ifpZaP0ut91Jn_ON-eWp68v_gvxZnQOyAhxgKpfwzTA-U6jVhKOuXNj_tKnEa___9DzP5lWw</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Szewczyk, Michael T</creator><creator>Soefje, Scott A</creator><general>Oxford University Press</general><general>Copyright Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210101</creationdate><title>Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration</title><author>Szewczyk, Michael T ; Soefje, Scott A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3219-4dd08a44299481e79c8f2c36d4a1d1d4e2c1ff548edf18bdd231caeb821923ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Szewczyk, Michael T</creatorcontrib><creatorcontrib>Soefje, Scott A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of health-system pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Szewczyk, Michael T</au><au>Soefje, Scott A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration</atitle><jtitle>American journal of health-system pharmacy</jtitle><addtitle>Am J Health Syst Pharm</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>78</volume><issue>1</issue><spage>60</spage><epage>64</epage><pages>60-64</pages><issn>1079-2082</issn><eissn>1535-2900</eissn><abstract>Abstract
Purpose
To describe the development of an innovative process to deliver bacillus Calmette-Guérin (BCG) to an offsite urology clinic for bladder instillation.
Summary
The use of BCG, a live virus vaccine for treatment of patients with localized cancer of the urinary bladder, has created many logistical problems for hospitals and infusion center pharmacies. Due to its short stability, the drug cannot be made ahead of time and coordination with a patient’s arrival at an infusion site is challenging. This becomes exceptionally challenging when a urology clinic has limited compounding capacity and/or is distant from the site of BCG medication preparation. This article describes an innovative process involving use of closed-system transfer devices (CSTDs) to allow for the administration of BCG in a urology clinic offsite from a medical center’s infusion center facilities.
Conclusion
The use of the CSTD allowed the patients to continue to receive bladder instillations at an offsite urology clinic without significantly disrupting compounding workflow at the small infusion center pharmacy that was the nearest to the clinic.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>33091117</pmid><doi>10.1093/ajhp/zxaa339</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1079-2082 |
ispartof | American journal of health-system pharmacy, 2021-01, Vol.78 (1), p.60-64 |
issn | 1079-2082 1535-2900 |
language | eng |
recordid | cdi_proquest_miscellaneous_2454131383 |
source | Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list) |
title | Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A49%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20an%20innovative%20delivery%20system%20for%20bacillus%20Calmette-Gu%C3%A9rin%20bladder%20administration&rft.jtitle=American%20journal%20of%20health-system%20pharmacy&rft.au=Szewczyk,%20Michael%20T&rft.date=2021-01-01&rft.volume=78&rft.issue=1&rft.spage=60&rft.epage=64&rft.pages=60-64&rft.issn=1079-2082&rft.eissn=1535-2900&rft_id=info:doi/10.1093/ajhp/zxaa339&rft_dat=%3Cproquest_cross%3E2454131383%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3219-4dd08a44299481e79c8f2c36d4a1d1d4e2c1ff548edf18bdd231caeb821923ec3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2454131383&rft_id=info:pmid/33091117&rft_oup_id=10.1093/ajhp/zxaa339&rfr_iscdi=true |